Log in

NASDAQ:CDXCChromadex Stock Price, Forecast & News

$4.77
-0.01 (-0.21 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.75
Now: $4.77
$4.98
50-Day Range
$3.37
MA: $4.56
$5.52
52-Week Range
$2.50
Now: $4.77
$5.80
Volume229,170 shs
Average Volume447,921 shs
Market Capitalization$293.25 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and finished products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is based in Irvine, California.
Read More
Chromadex logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.91 out of 5 stars


Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDXC
CUSIPN/A
Phone310-388-6706

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$46.29 million
Book Value$0.27 per share

Profitability

Net Income$-32,150,000.00

Miscellaneous

Employees100
Market Cap$293.25 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive CDXC News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.

Chromadex (NASDAQ:CDXC) Frequently Asked Questions

How has Chromadex's stock been impacted by COVID-19 (Coronavirus)?

Chromadex's stock was trading at $3.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CDXC stock has increased by 29.6% and is now trading at $4.77. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Chromadex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chromadex.

When is Chromadex's next earnings date?

Chromadex is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Chromadex.

How were Chromadex's earnings last quarter?

Chromadex Corp (NASDAQ:CDXC) issued its earnings results on Monday, May, 11th. The company reported ($0.10) EPS for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.01. The firm earned $14.35 million during the quarter, compared to the consensus estimate of $13.76 million. Chromadex had a negative net margin of 58.73% and a negative return on equity of 132.48%. View Chromadex's earnings history.

What price target have analysts set for CDXC?

3 analysts have issued 12-month price objectives for Chromadex's shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate Chromadex's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 25.8% from the stock's current price. View analysts' price targets for Chromadex.

Has Chromadex been receiving favorable news coverage?

News headlines about CDXC stock have trended somewhat positive on Friday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Chromadex earned a news impact score of 1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View the latest news aboutChromadex.

Are investors shorting Chromadex?

Chromadex saw a drop in short interest in May. As of May 15th, there was short interest totaling 2,850,000 shares, a drop of 17.9% from the April 30th total of 3,470,000 shares. Based on an average trading volume of 526,800 shares, the short-interest ratio is presently 5.4 days. Currently, 7.5% of the company's stock are short sold. View Chromadex's Current Options Chain.

Who are some of Chromadex's key competitors?

What other stocks do shareholders of Chromadex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chromadex investors own include Heron Therapeutics (HRTX), Tilray (TLRY), TransEnterix (TRXC), Athersys (ATHX), Glu Mobile (GLUU), Axsome Therapeutics (AXSM), CELYAD SA/ADR (CYAD), Mesoblast (MESO), Sorrento Therapeutics (SRNE) and FuelCell Energy (FCEL).

Who are Chromadex's key executives?

Chromadex's management team includes the following people:
  • Mr. Frank Louis Jaksch Jr., Co-Founder & Exec. Chairman (Age 51)
  • Mr. Robert N. Fried, CEO & Director (Age 59)
  • Mr. Kevin M. Farr, Chief Financial Officer (Age 61)
  • Mr. Ben Shichman, Chief Technology Officer
  • Dr. Matthew Roberts, Chief Scientific Officer & Sr. VP of Innovation

What is Chromadex's stock symbol?

Chromadex trades on the NASDAQ under the ticker symbol "CDXC."

Who are Chromadex's major shareholders?

Chromadex's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (4.13%), Tieton Capital Management LLC (2.45%), State Street Corp (1.17%), Geode Capital Management LLC (0.98%), UBS Group AG (0.37%) and Sargent Investment Group LLC (0.16%). Company insiders that own Chromadex stock include Kevin M Farr, Robert N Fried and Stephen A Block. View institutional ownership trends for Chromadex.

Which major investors are selling Chromadex stock?

CDXC stock was sold by a variety of institutional investors in the last quarter, including Tieton Capital Management LLC, Morgan Stanley, UBS Group AG, Group One Trading L.P., Raymond James Financial Services Advisors Inc., and BlackRock Inc.. View insider buying and selling activity for Chromadex.

Which major investors are buying Chromadex stock?

CDXC stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Sargent Investment Group LLC, State Street Corp, Alliancebernstein L.P., BNP Paribas Arbitrage SA, Wells Fargo & Company MN, and Citigroup Inc.. Company insiders that have bought Chromadex stock in the last two years include Kevin M Farr, and Robert N Fried. View insider buying and selling activity for Chromadex.

How do I buy shares of Chromadex?

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chromadex's stock price today?

One share of CDXC stock can currently be purchased for approximately $4.77.

How big of a company is Chromadex?

Chromadex has a market capitalization of $293.25 million and generates $46.29 million in revenue each year. The company earns $-32,150,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Chromadex employs 100 workers across the globe.

What is Chromadex's official website?

The official website for Chromadex is www.chromadex.com.

How can I contact Chromadex?

Chromadex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at 310-388-6706 or via email at investorrela[email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.